Stiles Financial Services Inc Sells 103 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Oct 10th, 2023

Stiles Financial Services Inc lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 17,541 shares of the company’s stock after selling 103 shares during the period. Johnson & Johnson makes up approximately 1.4% of Stiles Financial Services Inc’s holdings, making the stock its 13th largest position. Stiles Financial Services Inc’s holdings in Johnson & Johnson were worth $2,903,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Atlantic Private Wealth LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $32,000. Ruedi Wealth Management Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $42,000. 25 LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at approximately $55,000. Horizons Wealth Management raised its holdings in Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after acquiring an additional 346 shares in the last quarter. Finally, Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $66,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Wells Fargo & Company cut their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Finally, Barclays lowered their price objective on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research note on Friday, September 8th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $171.06.

Get Our Latest Stock Analysis on Johnson & Johnson

Insider Buying and Selling at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

Shares of JNJ opened at $158.53 on Tuesday. The firm has a market capitalization of $412.01 billion, a price-to-earnings ratio of 32.09, a PEG ratio of 3.19 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The business’s fifty day moving average price is $164.12 and its two-hundred day moving average price is $162.46. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $2.59 EPS. On average, analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s payout ratio is 96.36%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.